VIGIL NEUROSCIENCE INC (VIGL) Stock News
NASDAQ:VIGL - Nasdaq - US92673K1088 - Common Stock - Currency: USD
VIGL Latest News, Press Relases and Analysis
On Tuesday, there are stocks with unusual volume. Let's take a look.
Join us as we delve into today's session and uncover the stocks that are standing out with unusual volume.
Which stocks have an unusual volume on Friday?
In today's session, these stocks are experiencing unusual volume.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SGMA, VIGL, STRR on Behalf of Shareholders
Wall Street Analysts Believe Vigil Neuroscience (VIGL) Could Rally 86.68%: Here's is How to Trade
The consensus price target hints at an 86.7% upside potential for Vigil Neuroscience (VIGL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
US Stocks Likely To Open On A Mixed Note: 'Nothing Good Happens Above A 5% Yield,' Says Expert
U.S. stock futures were fluctuating on Friday after a mixed close on Thursday. Futures of benchmark indices were mixed in premarket.
Vigil Neuroscience to be acquired by Sanofi for $8.00 per share
Vigil Neuroscience (VIGL) and Sanofi (SNY) announced that it has entered into a definitive merger agreement pursuant to which Sanofi will acquire Vigil for an upfront payment of $8.00 per share of common stock in cash. Vigil shareholders will also receive a non-tradeable contingent value right entitling the holder to potentially receive an additional $2.00 per share in cash payable following the first commercial sale of VG-3927 if achieved within a specific period. The total equity value of the
Vigil Neuroscience Stock Triples as Drugmaker Agrees to Acquisition by Sanofi
Vigil Neuroscience shares jumped nearly 250% Thursday after the Alzheimer's disease drug developer reached a deal to be acquired by French pharmaceutical giant Sanofi.
Better Weight Loss Stock: Amgen or Viking Therapeutics?
Amgen's weight loss candidate reported mixed phase 2 data, but the company has other weapons. Viking Therapeutics' leading anti-obesity program aced mid-stage studies, and it's not its only promising candidate. Deciding between these two stocks might come down to each investor's style, priorities, and risk tolerance.
Sanofi to Join Alzheimer's Space With Vigil Neuroscience Buyout
SNY inks an agreement to acquire VIGL and its pipeline candidate VG-3927, which is being developed to treat Alzheimer's disease.
Sanofi Inks A $470 Million Alzheimer's Deal, Sending This Dollar Stock Flying
The company is working on an Alzheimer's treatment that increases the activity of TREM2, a neuroinflammation target.
Vigil Neuroscience Stock Triples Pre-market On Acquisition By Sanofi: Retail Goes Super Bullish
Under the terms of the deal, Sanofi will acquire all outstanding common shares of Vigil for $8 per share in cash at closing.
Shareholder Alert: The Ademi Firm Investigates Whether Vigil Neuroscience Inc. Is Obtaining a Fair Price for Its Public Shareholders
Apple Brings Back Fortnite to U.S. App Store After Five-Year Absence
Apple Inc. (NASDAQ:AAPL) has authorized Fortnite’s re-entry into the US App Store, bringing an end to a five-year absence that started in 2020. The ruling comes after the court warned the firm on Monday to either allow the app or settle its conflict with Epic Games. Epic submitted Fortnite for assessment on May 9, but […]
Victoria’s Secret Uses ‘Poison Pill’ as Brett Blundy’s BBRC Increases Stake
On May 20, Australian billionaire Brett Blundy’s investment vehicle, BBRC International Private Limited, increased its stake in the lingerie manufacturer, Victoria’s Secret & Co. (NYSE:VSCO), to implement a limited-duration shareholder rights plan. According to Board Chair Donna James, the “poison pill” prevents anyone from taking over the business without paying all shareholders a fair premium. […]
Nippon Steel Remains Committed to Complete U.S. Steel Takeover
Nippon Steel Corporation (OTC:NPSCY) of Japan is still determined to buy out United States Steel Corporation (NYSE:X) in its entirety, even in the face of regulatory scrutiny. The business’s plan was verified by Vice Chairman Takahiro Mori before the May 21 deadline for the CFIUS’s updated national security review, which is overseen by U.S. Treasury […]
Chevron Eyes Major Oil and Gas Assets in Indonesia
Chevron Corporation (NYSE:CVX) has shown interest in tapping into Indonesia’s oil and gas assets with substantial reserves, according to Djoko Siswanto, head of the country’s upstream regulator SKK Migas, who made the statement on May 20. Djoko noted that Chevron is evaluating blocks that could hold approximately 15 trillion cubic feet of gas, though the […]
VIGL Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Vigil Neuroscience, Inc. is Fair to Shareholders
BOJ policymaker rules out intervention to stem bond yield spike
TOKYO (Reuters) -Bank of Japan board member Asahi Noguchi said on Thursday he saw no need for the central bank to intervene in the bond market to stem recent sharp rises in super-long yields, describing the moves as "rapid but not abnormal." Noguchi, a former academic regarded as one of the central bank board's dovish members, also said the central bank must pause its interest rate hikes for the time being until there is more clarity on the impact of U.S. tariffs on the economy. "When the outlook is so uncertain, there's no point acting on interest rates," he told a news conference, stressing the need to put off raising rates for the time being.
Sanofi Set to Acquire Vigil Neuroscience in $470 Million Deal
Sanofi (NASDAQ:SNY) has announced a deal to acquire Vigil Neuroscience, a clinical-stage biotech company, for around $470 million, aiming to strengthen its research pipeline with a potential new Alzheimer’s treatment. Under the agreement, Vigil shareholders will receive $8 per share, along with the possibility of an extra $2 per share through a contingent value right […]
Why Moderna, Inc. (MRNA) Crashed Today
We recently published a list of 10 Firms Drenched in Red Today. In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against other firms that are drenched in red today. Ten companies pulled back on Wednesday, booking hefty losses during the trading session, with investor sentiment weighed down by […]
Keysight Technologies, Inc. (KEYS) Beats Earnings, JP Morgan Raises Price Target to $177
We recently published a list of 12 AI Stocks on Analysts’ Radar. In this article, we are going to take a look at where Keysight Technologies, Inc. (NYSE:KEYS) stands against other AI stocks on analysts’ radar. The recently imposed US sanctions on chip use have angered China. In recent news, the country has stated that […]
Dell Technologies Inc. (DELL) Talks AI at Tech Event, Analyst Reaffirms $120 Price Target
We recently published a list of 12 AI Stocks on Analysts’ Radar. In this article, we are going to take a look at where Dell Technologies Inc. (NYSE:DELL) stands against other AI stocks on analysts’ radar. The recently imposed US sanctions on chip use have angered China. In recent news, the country has stated that […]
Vigil Neuroscience Enters into Definitive Merger Agreement to be Acquired by Sanofi
Mentions: SNY
Vigil Neuroscience Enters into Definitive Merger Agreement to be Acquired by Sanofi
- Vigil’s shareholders to receive up to $10.00 per share in cash, comprised of $8.00 per share in cash at closing and a non-tradeable contingent value...
Why Reddit Stock Got Hammered on Wednesday
An analyst tracking the stock made a double-digit cut to his price target. One of the more up-and-coming social media stocks in recent times, Reddit (NYSE: RDDT), went down quite a bit on Wednesday. Despite the double-digit adjustment, he left his "neutral" recommendation on the shares unchanged.
Vigil Neuroscience Reports First Quarter 2025 Financial Results and Provides Recent Business Updates
Vigil Neuroscience Reports First Quarter 2025 Financial Results and Provides Recent Business Updates
– On track to report final analysis from IGNITE Phase 2 clinical trial evaluating iluzanebart in ALSP in Q2 2025 – – Plans to initiate Phase 2 clinical...